Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer-Reference-Cited by-同舟云学术

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer

Published:2022-03-09 Issue:6 Volume:31 Page:567-591
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Agostinetto Elisa¹²^ORCID,Losurdo Agnese³,Nader-Marta Guilherme¹^ORCID,Santoro Armando²³,Punie Kevin⁴,Barroso Romualdo⁵,Popovic Lazar⁶,Solinas Cinzia⁷,Kok Marleen⁸^ORCID,de Azambuja Evandro¹^ORCID,Lambertini Matteo⁹¹⁰^ORCID

Affiliation:

1. Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Bruxelles, Belgium

2. Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy

3. Humanitas Research Hospital – IRCCS, Humanitas Cancer Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy

4. Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

5. Oncology Center, Hospital Sirio-Libanes, Brasilia, Brazil

6. Oncology Institute of Vojvodina, Faculty of Medicine, University Novi Sad, Novi Sad, Serbia

7. Medical Oncology, ATS Sardegna, Ospedale San Francesco, Nuoro, Italy

8. Departments of Medical Oncology, Tumor Biology & Immunology. Netherlands Cancer Institute, Amsterdam, Netherlands

9. Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy

10. Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2049232

Reference105 articles.

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER website, April 2019. https://seer.cancer.gov/archive/csr/1975_2016/

2. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

4. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

5. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD44/PD-L1-mediated networks in drug resistance and immune evasion of breast cancer stem cells: Promising targets of natural compounds;International Immunopharmacology;2024-09

2. Heterogeneity in the Primary Lesions of invasive micropapillary breast carcinoma.;Current Problems in Cancer: Case Reports;2024-09

3. Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K;Biochemical Pharmacology;2024-08

4. Expression and function of cytokine interleukin-22 gene in the tumor microenvironment of triple negative breast cancer;Cytokine;2024-07

5. Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents;Cancer Management and Research;2024-07